Trials / Unknown
UnknownNCT05302843
A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors
A Phase 1，Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ascendind Doses of BPI-28592 in Subjects With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Betta Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-labe Phase I study of BPI-28592 for the treatment of patients with solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPI-28592 | Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592 |
Timeline
- Start date
- 2021-03-22
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2022-03-31
- Last updated
- 2022-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05302843. Inclusion in this directory is not an endorsement.